Although KARS inhibition should be an effective strategy to treat pancreatic cancer, the rapid recurrence of primary and metastatic cancer following reactivation of KRAS supports the existence of dormant cancer cells in the animal model [164]. Here, KRAS is linked to familial pancreatic carcinoma.